ANI Pharmaceuticals has been granted a patent for a powder for oral suspension containing highly pure hydrochlorothiazide, useful for treating hypertension and edema. The composition includes specific percentages of the active ingredient, thickening agent, and excipient, with a pH range of 3.5 to 5.5 when reconstituted in water. GlobalData’s report on ANI Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on ANI Pharmaceuticals, was a key innovation area identified from patents. ANI Pharmaceuticals's grant share as of February 2024 was 56%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11878022B2) discloses a powder for oral suspension designed for oral administration. The composition includes 3% w/w to 5% w/w of hydrochlorothiazide, along with at least one thickening agent and a pharmaceutically acceptable excipient. Notably, the powder, when mixed with 5 mL of water, achieves a pH range of 3.5 to 5.5. The patent further specifies variations in the hydrochlorothiazide content within the powder, ranging from 3.5% w/w to 4.4% w/w, or a fixed percentage of 4.2% w/w. Additionally, the powder is formulated to have a water content not exceeding 0.8% w/w.
Moreover, the patent outlines the inclusion of specific thickening agents, such as xanthan gum, within the powder composition, ranging from 0.4% w/w to 5% w/w. The formulation also incorporates various pharmaceutically acceptable excipients, including preservatives and sweeteners, in specified amounts. These excipients serve to enhance the stability and palatability of the oral suspension. The patent further extends to cover an oral liquid suspension derived from the powder, which can be administered to treat conditions like edema and hypertension. The method of treatment involves providing a therapeutically effective amount of the oral liquid suspension to achieve specific pharmacokinetic parameters in patients.
To know more about GlobalData’s detailed insights on ANI Pharmaceuticals, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
